MRSA: Diagnostic test that uses novel technology receives FDA nod

The U.S. Food and Drug Administration authorized marketing of a new diagnostic test based on bacterial viability and novel technology to detect Methicillin-resistant Staphylococcus aureus (MRSA) bacterial colonization, a widespread cause of hospital-acquired infections. The cobas vivoDx MRSA diagnostic test may allow health care professionals to evaluate patients for colonization with MRSA bacteria more quickly than ["]

The post MRSA: Diagnostic test that uses novel technology receives FDA nod appeared first on Outbreak News Today.